David L. Nathan, MD, DLFAPA is a Princeton, New Jersey based psychiatrist, consultant, and educator, working exclusively through Princeton Psychiatry & Consulting, LLC. He is also a professional speaker and published author on diverse academic subjects in history and science.

Originally from the Philadelphia area, Dr. Nathan graduated magna cum laude from Princeton University. He received his M.D. from the University of Pennsylvania School of Medicine, where he distinguished himself in the creative design and development of medical education software. He subsequently completed his residency at McLean Hospital, the nation’s premier psychiatric hospital and an affiliate of Harvard Medical School.

Dr. Nathan has served as the Director of Continuing Medical Education for Penn Medicine Princeton Health (PMPH) since 2008 and the Director of Professional Education for Princeton House Behavioral Health (PHBH) since 1999. He is board certified in psychiatry by the American Board of Psychiatry and Neurology, and he remains involved in teaching as a Clinical Associate Professor at the Rutgers Robert Wood Johnson Medical School (RWJMS). He is a Distinguished Life Fellow of the American Psychiatric Association, the highest membership honor bestowed by the APA.

Dr. Nathan is a leading advocate for evidence-based changes in drug policy, following principles of public health and social justice. He is the founder and past president of Doctors for Drug Policy Reform (D4DPR). He has testified extensively before legislative bodies in states around the country, and was one of two physicians to testify at the U.S. House Judiciary Committee’s first hearing on cannabis legalization. His views on drug policy do not necessarily reflect those of PMPH or PHBH.

Dr. Nathan was a founding steering committee of New Jersey United for Marijuana Reform (NJUMR), a coalition of the New Jersey chapters of the ACLU, NAACP, and other organizations that was chiefly responsible for the legalization and regulation of cannabis for adults in New Jersey. He is a leader in the development of labeling standards for the regulated cannabis industry, including evidence-based product warnings and a standardized cannabis information label. Dr. Nathan is the principal designer of the International Intoxicating Cannabinoid Product Symbol (ASTM D8441), which has been adopted in numerous U.S. states since its introduction in 2022.